Predictive and Prognostic Value of Blood Cell Ratios in Patients with Metastatic Renal Cell Carcinoma Treated with Pazopanib

Proposal
628

Title of Proposed Research

Lead Researcher

Arnoud J. Templeton, MD

Affiliation

Princess Margaret Cancer Centre
Department of Medicine, University of Toronto
Toronto, Ontario, CA

Funding Source

This research will be funded through grants received by Dr. J. Knox (Princess Margaret Cancer Centre, Toronto, Canada)

Potential Conflicts of Interest

Data Sharing Agreement Date

30 January 2014

Lay Summary

LAY SUMMARY: Many patients with advanced kidney cancer wish to receive information about the likelihood to respond to treatments like pazopanib and about their life expectancy. Groups with different expectation of survival are based on clinical and disease-related factors and research to improve their accuracy is an ongoing need. We will investigate the predictive value of a readily available and inexpensive marker, based on blood counts determined in routine practice. It is hoped to establish a marker that is helpful for treating physicians and their patients when discussing the chance of response to pazopanib outcome of advanced kidney cancer.

Study Data Provided

[{ "PostingID": 461, "Title": "GSK-VEG105192", "Description": "Medicine: pazopanib, Condition: Carcinoma, Renal Cell, Phase: 3, GSK Clinical Study ID: VEG105192, Sponsor: GSK." },{ "PostingID": 462, "Title": "GSK-VEG102616", "Description": "Medicine: pazopanib, Condition: Carcinoma, Renal Cell, Phase: 2, GSK Clinical Study ID: VEG102616, Sponsor: GSK." }]

Statistical Analysis Plan

Publication Citation

The publication citation will be added after the research is published.